- Develop biomarker-based diagnostic approaches to assess HR+/HER2- MBC progression and identify optimal treatment options
- Assess clinical trial data for current and emerging agents for HR+/HER2- MBC and impact on the treatment paradigm for treatment plans
- Implement shared decision-making strategies to optimize AE management and enhance treatment adherence in clinical practice
Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer | Minnesota
April 10, 2025
5:15 PM - 6:15 PM Central Time
Virtual Regional Meeting | Minnesota
Overview:
This live, virtual symposium will bring together a world-renowned expert in the management of breast cancer with a local community oncologist to discuss the role of next-generation selective estrogen receptor degraders (SERDs) in the treatment of hormone receptor–positive, HER2-negative (HR+/HER2-) breast cancer. In this program, the faculty will review recent clinical updates evaluating SERDs for metastatic HR+/HER2- breast cancer and discuss best practices to implement biomarker testing to guide treatment decisions. Case-based conversations will be included throughout the program to provide clinicians with the key takeaways of all the data. Participants will have the opportunity to reflect on how experts make clinical decisions with regards to initiating and sequencing therapy, as well as best practices in managing adverse events.
Learning Objectives:
Upon completion of this activity, participants will be able to:
Target Audience:
This educational program is directed toward community-based medical oncologists, surgeons, advanced practice providers, nurses, and other healthcare professionals involved in the treatment of breast cancer.
Accreditation/Credit Designation:
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Acknowledgment of Educational Support
This activity is supported by an educational grant from Stemline Therapeutics, Inc.
Have a question for the PER® team?
Email: info@gotoper.com
Health & Safety
Physicians’ Education Resource®, LLC’s (PER®’s) top priority is the safety and security of our attendees, faculty, exhibitors, staff, and operational personnel. As we develop the programming for this activity, PER® is working diligently to implement health and safety protocols based on the advice of health experts and the latest guidelines and local regulations to optimize health and safety conditions for attendees during the event. Please note that attendance at any public event increases the risk of contracting a communicable illness. Attendees assume all risk associated with attendance. Any attendees who feel ill, regardless of their symptoms, should not attend this event.
2 Commerce Drive Cranbury, NJ 08512
info@gotoper.com
Copyright ©2025
Physicians' Education Resource®, LLC.
All rights reserved
.png)